Investigational Drug Information for LOXO-305
✉ Email this page to a colleague
What is the development status for investigational drug LOXO-305?
LOXO-305 is an investigational drug.
There have been 26 clinical trials for LOXO-305.
The most recent clinical trial was a Phase 1 trial, which was initiated on March 5th 2021.
The most common disease conditions in clinical trials are Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, and Leukemia, Lymphoid. The leading clinical trial sponsors are Loxo Oncology, Inc., Eli Lilly and Company, and M.D. Anderson Cancer Center.
There are four US patents protecting this investigational drug and sixty-two international patents.
Summary for LOXO-305
| US Patents | 4 |
| International Patents | 62 |
| US Patent Applications | 9 |
| WIPO Patent Applications | 6 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2021-03-05) |
| Vendors | 28 |
Recent Clinical Trials for LOXO-305
| Title | Sponsor | Phase |
|---|---|---|
| LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies | Medical College of Wisconsin | Phase 1 |
| A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis | Eli Lilly and Company | Phase 2 |
| A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis | Loxo Oncology, Inc. | Phase 2 |
Clinical Trial Summary for LOXO-305
Top disease conditions for LOXO-305
Top clinical trial sponsors for LOXO-305
US Patents for LOXO-305
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| LOXO-305 | ⤷ Sign Up | Compounds useful as kinase inhibitors | Loxo Oncology, Inc. (Stamford, CT) | ⤷ Sign Up |
| LOXO-305 | ⤷ Sign Up | Compounds useful as kinase inhibitors | Loxo Oncology Inc. | ⤷ Sign Up |
| LOXO-305 | ⤷ Sign Up | Compounds useful as kinase inhibitors | Loxo Oncology, Inc. (Stamford, CT) | ⤷ Sign Up |
| LOXO-305 | ⤷ Sign Up | ⤷ Sign Up | ||
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for LOXO-305
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| LOXO-305 | Australia | AU2016373530 | 2035-12-16 | ⤷ Sign Up |
| LOXO-305 | Australia | AU2021201811 | 2035-12-16 | ⤷ Sign Up |
| LOXO-305 | Australia | AU2021225161 | 2035-12-16 | ⤷ Sign Up |
| LOXO-305 | Australia | AU2021225162 | 2035-12-16 | ⤷ Sign Up |
| LOXO-305 | Brazil | BR112018012341 | 2035-12-16 | ⤷ Sign Up |
| LOXO-305 | Canada | CA3008488 | 2035-12-16 | ⤷ Sign Up |
| LOXO-305 | Chile | CL2018001591 | 2035-12-16 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
